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Abstract
Myeloid sarcomas are extramedullary accumulations of immature myeloid cells that may present with or without evidence
of pathologic involvement of the bone marrow or peripheral blood, and often coincide with or precede a diagnosis of acute
myeloid leukemia (AML). A dearth of experimental models has hampered the study of myeloid sarcomas and led us to
establish a new system in which tumor induction can be evaluated in an easily accessible non-hematopoietic tissue
compartment. Using ex-vivo transduction of oncogenic Kras(G12V) into p16/p19
2/2 bone marrow cells, we generated
transplantable leukemia-initiating cells that rapidly induced tumor formation in the skeletal muscle of immunocompro-
mised NOD.SCID mice. In this model, murine histiocytic sarcomas, equivalent to human myeloid sarcomas, emerged at the
injection site 30–50 days after cell implantation and consisted of tightly packed monotypic cells that were CD48+, CD47+
and Mac1+, with low or absent expression of other hematopoietic lineage markers. Tumor cells also infiltrated the bone
marrow, spleen and other non-hematopoietic organs of tumor-bearing animals, leading to systemic illness (leukemia) within
two weeks of tumor detection. P16/p19
2/2; Kras(G12V) myeloid sarcomas were multi-clonal, with dominant clones selected
during secondary transplantation. The systemic leukemic phenotypes exhibited by histiocytic sarcoma-bearing mice were
nearly identical to those of animals in which leukemia was introduced by intravenous transplantation of the same donor
cells. Moreover, murine histiocytic sarcoma could be similarly induced by intramuscular injection of MLL-AF9 leukemia cells.
This study establishes a novel, transplantable model of murine histiocytic/myeloid sarcoma that recapitulates the natural
progression of these malignancies to systemic disease and indicates a cell autonomous leukemogenic mechanism.
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Introduction
Myeloid sarcomas (also known as chloromas) are extramedul-
lary tumors composed of myeloid lineage cells. Myeloid sarcomas
typically present in the setting of acute myeloid leukemia (AML) or
in conjunction with transformation of a myelodysplastic syndrome
(MDS) [1]. Myeloid sarcomas without bone marrow or peripheral
blood involvement often precede the development of new or
recurrent leukemia [2–4]. Myeloid sarcomas arise predominantly
in the bone, soft tissue, lymph nodes, and skin, but essentially any
part of the body can be affected [5–8]. Treatment of these
malignancies generally follows the same therapeutic algorithms
established for their systemic, leukemic counterparts and may
additionally involve local radiation [2]. The prognostic signifi-
cance of myeloid sarcoma at first diagnosis of AML remains
somewhat unclear. An association with less favorable disease
outcomes has been discussed [9,10], and a recent paper showed
that orbital and CNS (central nervous system) myeloid sarcoma in
children have a significantly better survival than myeloid sarcoma
at other organ sites or AML without myeloid sarcoma [11].
The relative dearth of knowledge regarding the biology of
myeloid malignancies arising in extramedullary tissues led us to
comparatively evaluate myeloid tumors initiated in either skeletal
muscle or in blood following introduction of identical oncogenetic
lesions (i.e. oncogenic KrasG12(V) and loss of p16
Ink4A/p19
Arf). Both
oncogenic lesions are strongly associated with human and mouse
hematopoietic malignancies [12–16]. Moreover, constitutively
activated Kras(G12D) combined with p16/p19 deficiency induces
aggressive cancers in a number of non-hematopoietic tissues and
organs in mice [17–24]. We therefore introduced oncogenic Kras
into p16p19
2/2 bone marrow cells by ex vivo gene transduction,
and then transplanted these genetically altered cells to induce
systemic leukemias (by retro-orbital injection), as well as to
produce the first transplantable model of murine histiocytic
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CID mice). Irrespective of transplantation location, tumor cells
shared similar morphological and phenotypic features, and
histiocytic sarcomas initiated in mouse skeletal muscle seeded
systemic disease within weeks of emergence, recapitulating the
leukemic progression seen in humans. Finally, murine histiocytic
sarcomas could be induced using genetic lesions distinct from p16/
p19
2/2; Kras, i.e. MLL-AF9, thereby suggesting that the murine
histiocytic induction model described here can be applied to study
a broad spectrum of hematopoietic malignancies. In summary, this
work suggests that the phenotype of hematopoietic neoplasms is
largely independent of the tissue environment in which they
develop and provides a rapid and reproducible platform to
generate and study the behavior of extramedullary hematopoietic
tumors.
Results
Loss of p16
Ink4A/p19
Arf cooperates with oncogenic
Kras(G12V) to induce leukemia
Bone marrow (BM) cells were isolated from p16p19
2/2 mice,
infected with Kras(G12V) in a GFP-tagged pGIPZ lentivirus, and
injected retro-orbitally into immunodeficient NOD.SCID mice.
All recipient mice showed significant weight loss, anemia and
splenomegaly, and were moribund 35–60 days post injection (32
mice evaluated in 4 independent experiments, Fig. 1A–C). In
contrast, p16p19
2/2 BM cells infected with control (Ctrl) virus
(GFP-tagged empty pGIPZ vector) failed to induce leukemia in 12
out of 14 recipients (2 of the 14 recipients died without clinically
apparent tumors but could not be subjected to necropsy due to
autolysis) (Fig. 1A). Likewise, wild-type (WT) C57BL/6 BM cells
infected with Kras(G12V) induced leukemias in only 2 out of 10
injected NOD.SCID mice. Thus, consistent with previous reports
[15,25–28], the combination of oncogenic Kras and p16p19-
deficiency potently drives leukemogenesis in mouse BM cells,
whereas either of these two lesions alone shows limited leukemo-
genic potential within an 8 to 10- week follow up time.
Significantly, prior reports indicate that even with longer follow
up (8–9 months), p16p19-deficiency or oncogenic Kras alone
produces hematopoietic neoplasms (mostly B- or T-lymphomas
and T cell leukemias) with relatively low efficiency [15,29].
The spleen and liver of leukemic mice originally injected with
p16p19
2/2; Kras(G12V) BM cells, exhibited extramedullary
hematopoiesis and massive infiltration by intermediate to large
size cells with oval, irregularly folded nuclei, prominent nucleoli,
and a moderate to large amount of eosinophilic cytoplasm most
consistent with involvement of a non-lymphoid hematopoietic
malignancy (Fig. 1D). In contrast, the bone marrow of these mice
contained variable foci of immature intermediate to large size cells
with round or oval, irregular nuclei, prominent nucleoli and
moderate cytoplasm. Peripheral blood smears revealed polychro-
masia and marked reticulocytosis, suggestive of extramedullary
hematopoiesis; however, no blasts were noted in the peripheral
blood (data not shown). Taken together, this constellation of
findings is consistent with the development of murine histiocytic
leukemia, equivalent to human acute myeloid leukemia, after
retro-orbital injection of p16p19
2/
2; Kras bone marrow cells [30].
The immunophenotype of tumor-derived GFP+ cells in the
bone marrow (containing 5.262.3% GFP+ cells; n=10) and
spleen (containing 10.763.5% GFP
+ cells; n=10) of leukemic
mice was evaluated by flow cytometry. The majority of GFP+
tumor cells expressed CD48 (99.360.7%), CD47 (89.566.9%)
and Mac1 (74.4614.7%), while expression of Gr1 (4.7362.65%),
B220 (1.3561.52%), CD4 (18.6616.8%), and Ter119
(3.1361.6%, Fig. 1E) was low or absent. Variable levels of CD8
(68.8614.9%) and CD71 (58.6616.8%) were seen in a subset of
mice (10 out of 32 animals examined). Although these data
indicate substantial heterogeneity in the leukemic clones propa-
gated in vivo, this antigen expression pattern is consistent overall
with an acute leukemia of myeloid phenotype.
Injection of p16p19
2/2; Kras(G12V) bone marrow cells in
the hindlimb induces localized histiocytic sarcoma
To model murine histiocytic/myeloid sarcoma in NOD.SCID
mice, we adopted an intramuscular transplantation system
previously established to induce rhabdomyosarcomas in skeletal
muscle [24]. The same donor cell population as in the retro-orbital
injection experiments described above was injected into the
gastrocnemius muscles of NOD.SCID mice following pre-injury
with cardiotoxin (n=46 individual mice, 5 independent experi-
ments; Table 1). 39 out of 46 animals receiving p16p19
2/2;
Kras(G12V) BM cells developed tumors at the site of injection
within 30–50 days (one additional mouse developed tumor at day
70, Table 1, Fig. S1). In parallel control experiments, NOD-SCID
mice receiving p16p19
2/2; Ctrl BM cells (n=16 mice, 3
independent experiments) or WT; Kras(G12V) BM cells (n=10
mice, 2 independent experiments) in the cardiotoxin pre-injured
gastrocnemius muscles produced no tumors (Table 1), nor did
C57BL/6 mice receiving p16p19
2/2; Kras(G12V) BM cells in pre-
injured muscles (0/10). To assess the influence of cardiotoxin pre-
injury on subsequent tumor development, p16p19
2/2; Kras(G12V)
BM cells were injected into the gastrocnemius muscles of an
additional cohort of NOD.SCID mice without cardiotoxin pre-
injury (n=10 mice, 2 independent experiments, Table 1). Tumor
frequency and latency were found to be independent of
cardiotoxin pre-injury (tumors developed in 84.8% of muscles
pre-injured by cardiotoxin injection and in 80% of uninjured
muscles, p=0.68).
Phenotypic analyses of tumor samples indicated that tumors
arising from p16p19
2/2; Kras(G12V) BM cells were comprised
mostly of immature GFP
+ monocytic cells (61.2613.9%, Fig. 2D).
The immunophenotype of GFP
+ tumor cells recovered from
muscle was highly similar to that of leukemic cells recovered from
mice transplanted retro-orbitally with p16p19
2/2; Kras(G12V) cells
(Fig. 1E), including high levels of CD48 (96.7763.6%), CD47
(81.09616.30%), and Mac1 (79.59618.91%), and low to absent
expression of CD4 (26.52625.54%), B220 (16.77616.4%),
Ter119 (15.5614.5%), CD71 (30.1615.4%), Gr1 (7.5468.4%),
and CD8 (9.2469.05%) (Fig. 2D). One notable exception was the
more frequent expression of CD8 by tumor cells recovered from
the bone marrow of mice transplanted retro-orbitally with
p16p19
2/2; Kras-transduced cells (68.8614.9% vs. 9.2469.05%,
Figs. 1E and 2D). In general, however, the immunophenotype of
the murine histiocytic neoplasm induced from p16p19
2/2;
Kras(G12V) BM cells appears to be independent of its primary
site and particular microenvironment.
Microscopic examination of tumor sections revealed extensive
infiltration of tumor cells into the muscle and surrounding adipose
tissue, with nearly complete destruction of normal muscle
architecture. Infiltrating cells were immature-appearing interme-
diate to large size cells with round or irregular nuclei, prominent
nucleoli and moderate to large amounts of cytoplasm (Fig. 3).
Scattered macrophages also were noted. Immunohistochemical
staining of primary tumor samples demonstrated that the tumor
cells were GFP
+ (consistent with flow cytometry analyses (Fig. 2D)
and with derivation from cells infected by Kras(G12V)-GFP virus)
and stained strongly for Mac2, consistent with a myeloid
phenotype. Tumors lacked expression of CD34, B220 and
Histiocytic Sarcoma in Mouse Muscle
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myeloperoxidase (MPO), which marks myeloid cells. Finally,
consistent with their aggressive growth kinetics, tumors exhibited
extensive reactivity for the cell proliferation marker Ki67 (detected
in 51.968.8% of all hematoxylin counter-stained cells, n=8 slides)
(Fig. 3). Based on their morphology and staining pattern, the
muscle tumors arising from p16p19
2/2; Kras(G12V) BM cells were
classified as histiocytic sarcomas (equivalent of human myeloid
sarcomas).
Dissemination of histiocytic sarcoma cells
Clinically, myeloid sarcomas often coincide with or precede the
diagnosis of new or recurrent acute myeloid leukemia [31].
Review of peripheral blood cell morphology of tumor bearing
mice revealed polychromasia and marked reticulocytosis consistent
with extramedullary hematopoiesis, as well as scattered immature
monocytic cells, consistent with monoblasts, in 2 animals (data not
shown). We also examined non-muscle hematopoietic tissues for
the presence of GFP
+ tumor cells. Nests of myeloid-appearing cells
were noted in the bone marrow, spleen and liver of tumor-bearing
animals (Fig. 4A). Enlarged spleens were observed in all tumor-
bearing mice (Fig. S1B). The immunophenotype of GFP
+ cells in
the bone marrow and spleen of sarcoma-bearing mice was
evaluated by flow cytometry. GFP
+ cells were CD48
hi
(95.463.1% in bone marrow, 98.960.9% in spleen), CD47
hi
(93.466.1% in bone marrow, 89.2611.7% in spleen), Mac1
mid/hi
(79.1612.5% in bone marrow, 70.5617.9% in spleen), and
B220
2/lo, CD4
2/lo, CD8
2/lo, Ter119
2/lo, and CD71
lo/mid
(Fig. 4B, 4C). This immunophenotype is highly consistent with
the phenotype of GFP+ cells isolated from primary histiocytic
sarcomas induced by intramuscular injection of p16p19
2/2;
Kras(G12V) BM cells (see Fig. 2D), as well as the phenotype of
GFP
+ leukemia cells derived by retro-orbital injection of BM cells
modified by the same oncogenetic lesions (see Fig. 1E). Thus,
induction of histiocytic sarcomas in skeletal muscle ultimately
results in systemic dissemination with involvement of bone
marrow, spleen and liver, thereby recapitulating the natural
Figure 1. Deficiency in p16
Ink4a p19
Arf cooperates with oncogenic Kras
G12V to produce myeloid leukemia in NOD.SCID mice. (A)
Kaplan-Meier survival curve for NOD.SCID recipients after transplantation with C57BL/6 bone marrow (BM) cells modified by the indicated
oncogenetic lesions. (B, C) Body weight and spleen weight analyses for NOD.SCID mice receiving p16p19
2/2; Kras(G12V) BM cells via intra-venous
transplantation at the time of sacrifice. Kras(G12V) and control groups were injected with cells and sacrificed for analysis at the same time points. (D)
Hematoxylin & eosin stain of bone, spleen and liver from NOD.SCID leukemic mice, indicating metastasis of myeloid leukemia cells (60x). (E)
Representative flow cytometry analysis of bone marrow from a NOD.SCID recipient of p16p19
2/2; Kras(G12V)-GFP expressing cells. Data are shown as
2-parameter contour plots for Forward Scatter (FSC) or for the indicated cell surface makers. Plots at right show data for cells previously gated for
viability (propidium iodide-, not shown) and GFP expression (leftmost plot).
doi:10.1371/journal.pone.0044044.g001
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Groups Recipient strain
No. of cells
transplanted
Tumor onset
time(days)
Cardio-toxin
Pre-injury Tumor/recipients
Ink4A/Arf
2/2; KrasG12V Primary Transplant
p16p19
2/2; KrasG12V NOD.SCID 5610
6 30–50, 70 Y 39/46
p16p19
2/2; Ctrl NOD.SCID 5610
6 N/A Y 0/16
WT; KrasG12V NOD.SCID 5610
6 N/A Y 2/10
p16p19
2/2; KrasG12V NOD.SCID 5610
6 60–70 N 8/10
p16p19
2/2; KrasG12V C57/B6 5610
6 N/A N 0/10
Secondary Transplant (GFP+ cells)
Group 1 NOD.SCID 100 K 24–40 Y 12/12
Group 2 NOD.SCID 10 K 25–40 Y 10/10
Group 3 NOD.SCID 2 K 50 Y 1/6
Group 4 NOD.SCID 200 N/A Y 0/2
MLL-AF9 tertiary transplant
MLL-AF9 2
nd BM cells NOD.SCID 1610
6 ,16 Y 15/15
Ds-Red control
BM cells
NOD.SCID 1610
6 N/A Y 0/5
Data are compiled for the three sets of experiments described in the text, including primary transplantation using p16p19
2/2; Kras(G12V) BM cells, secondary
transplantation using GFP
+ sorted tumor cells, and tertiary intra-muscular injection using MLL-AF9/DsRed leukemia BM cells. Data include source of cells used for
transplant, number of cells transplanted, time of tumor onset (days) after initial injection, whether the mice received cardiotoxin pre-injury, and percentage of mice
developing tumors among all recipients.
doi:10.1371/journal.pone.0044044.t001
Figure 2. Identical leukemogenic system generates histiocytic sarcoma in the hind limb of NOD.SCID mice when injected into the
gastrocnemius muscle. (A) Kaplan-Meier curve showing the fraction tumor-free mice at the indicated time after transplant of p16p19
2/2;
Kras(G12V)-GFP with or without cardiotoxin (CTX) pre-injury, or of p16p19
2/2 ;Ctrl or WT; Kras(G12V) cells, with CTX pre-injury, into the muscles of
NOD.SCID mice. (B, C) Body weight and spleen weight analyses at the time of sacrifice for NOD.SCID mice receiving p16p19
2/2; Kras(G12V) or
p16p19
2/2 ;Ctrl intra-muscular transplantation. Mice were sacrificed approximately 2 weeks after initial tumor detection. (D) Flow cytometry analysis
of a representative tumor sample from a NOD.SCID mouse bearing an p16p19
2/2; Kras(G12V)-GFP muscle tumor, revealing that most GFP
+ tumor cells
(gating shown on leftmost plot) are CD48
hi, CD47
hi, Mac1
hi, but Gr1
2/lo, B220
2/lo, CD4
2/lo, CD8
2/lo, CD71
2/lo and Ter119
2/lo.
doi:10.1371/journal.pone.0044044.g002
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systemic leukemias [30].
Histiocytic sarcoma is highly transplantable
The rapid growth of p16p19
2/2; Kras(G12V) histiocytic sarcoma
suggested that the initial seeding cell population contained clones
with leukemia-propagating ability. To test directly the tumor-
propagating potential of p16p19
2/2; Kras(G12V) histiocytic sarco-
mas, GFP
+ cells from primary tumors induced in the muscles of
primary NOD.SCID recipients were sorted using FACS and
defined numbers of sorted cells were transplanted into the
cardiotoxin pre-injured gastrocnemius muscle of secondary
NOD.SCID recipients (Fig. 5A). The frequency of tumor-
propagating cells within the GFP+ population was assessed by
limiting dilution analysis (using 200 to 100 000 cells per injection).
All mice receiving 100 000 (12/12 mice injected, 3 independent
experiments) or 10 000 (10/10 mice injected, 2 independent
experiments) GFP+ primary sarcoma cells developed tumors
within 25–40 days from injection (Table 1, Fig. S1C). These
studies suggest that the latency of secondary tumor formation is
markedly shorter than that of primary tumor formation (30–
50 days for tumor induction with 56106 p16p192/2; Kras(G12V)
BM cells, Table 1). The smallest number of GFP+ cells giving rise
to a histiocytic sarcoma in this analysis was 2 000 cells (1/6 mice
transplanted, 3 independent experiments), which yielded a tumor
50 days after transplant (Table 1). No tumors were detected in
recipients receiving 200 GFP+ cells (0/2 mice transplanted,
Table 1). Based on these data, the average frequency of tumor-
propagating cells in p16p19
2/2; Kras(G12V) histiocytic sarcomas
is 1/3 765 (confidence choice 95%, confidence intervals 1 870–7
578).
Secondary tumors exhibited histology similar to that of primary
tumors and were GFP
+ and Mac2
+ by immunohistochemistry
(Fig. 5B). Weak staining for MPO was detected among tumor
samples (Fig. 5B). Similar to primary tumor-bearing mice, the
livers and spleens of secondary recipients showed extensive
involvement by infiltrating myeloid cells (Fig. 5C, Fig. 4A).
Secondary tumors showed a high proliferative index (80616.4%
Ki67
+ of all hematoxylin counter-stained cells, n=5), and
peripheral blood smears lacked involvement by histiocytic sarcoma
(data not shown). Thus, p16p19
2/2; Kras(G12V) induced histio-
cytic sarcomas are highly transplantable in vivo.
Primary histiocytic sarcomas are oligo-clonal
The lentivirus-based strategy we employed to generate hema-
topoietic tumors has the inherent advantage that the transformed
cells are uniquely marked by viral integration [32], allowing direct
assessment of tumor clonality. We therefore asked if the p16p19
2/
2; Kras(G12V) histiocytic sarcomas were initiated by a single clone
or multiple clones of tumorigenic cells by analysis of proviral
integration sites. Genomic DNA was extracted from both primary
and secondary histiocytic sarcomas as well as from the BM of the
same set of tumor-bearing mice and subjected to Ligation-
Mediated PCR (LM-PCR) Assay [33]. Three PCR bands, on
average, were observed in each of the primary tumor samples,
indicating tumor oligoclonality (Fig. 6A). Sequencing of PCR
bands identified distinct loci in the murine genome, thus validating
that the LM-PCR products indicated bona fide proviral integration
sites (Fig. 6A, Fig. S2). Of note, sequencing of LM-PCR products
demonstrated that a single clone harboring an insertion in the
proximity of Ribosomal Protein S29 (RPS29) was present in one
set of matching primary and secondary transplanted tumors
(bands 10, 17, 18, Fig. 6 and Fig. S2). These data suggest that a
Figure 3. Histopathological examination of histiocytic sarcoma tissue sections. Hematoxylin & eosin staining of tumor (60x) indicating that
myeloid cells comprise a majority of the tumor cells. Immunohistochemistry staining of tumor samples shows positive staining for GFP, Ki67, Mac2,
and MPO, and negative staining of the non-myeloid hematopoietic lineage markers, B220 and Ter119 (40x).
doi:10.1371/journal.pone.0044044.g003
Histiocytic Sarcoma in Mouse Muscle
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selected during serial transplantation, explaining the shortened
tumor latency in secondary transplant recipients. We also
compared integration bands identified in tumors and bone
marrow specimens from 7 individual mice. 7 out of 7 BM samples
were polyclonal, and appeared to share subsets of the dominant
clones with the muscle-resident tumors (Fig. 6B). However, we also
detected additional novel bands in 4 out of 8 bone marrow
samples (Fig. 6B, marked by white arrows), suggesting differences
in selection forces on tumor cells in different microenvironments.
Histiocytic sarcoma can be induced using alternative
leukemogenic strategies
The very high rate of induction of histiocytic sarcoma observed
using p16p19
2/2; Kras(G12V) BM cells as a donor cell population
prompted us to ask whether this might be an intrinsic property of
this oncogenic combination, or whether histiocytic sarcomas can
be introduced in NOD.SCID mice using other leukemogenic
systems. We therefore acquired a leukemic cell sample in which
hematopoietic malignancy was induced using the MLL-AF9
retroviral system [34]. MLL-AF9-expressing cells, marked by co-
expression of Ds-Red, were harvested from secondary leukemic
BM and transplanted into the pre-injured gastrocnemius muscles
of NOD.SCID mice (Fig. S3A). All of these tertiary recipients
developed tumors in the injected hindlimb within 16 days (15/15
mice injected, Fig. S1D and Table 1), while control mice injected
with DS-Red labeled WT BM cells showed no tumor development
(0/5 mice injected, Table 1).
It previously has been reported [35] that the MLL-AF9
retroviral model induces acute myeloid leukemia in mice. MLL-
AF9 tumors in our model were consistently comprised of a
dominant DsRed
+ cell fraction (80.963.9%; Fig. S3B, n=10).
Similar to p16p19
2/2; Kras(G12V) histiocytic sarcomas (Fig. 2D)
and leukemias (Fig. 1E), MLL-AF9/DsRed tumors were CD48
hi
(95.862.4%), CD47
hi (95.362.9%), Mac1
hi (83.467.8%), Gr1
mid/
lo (20.262.4%), and B220
2/lo, CD4
2/lo, CD8
2/lo, Ter119
2/lo
(Fig. S3B, n=10). DsRed
+ cells also spread to distant hematopoi-
etic organs, including the BM and spleen, after tumor onset
(Fig. S3C). Of note, the percentage of DsRed
+ cells in both the
spleen and marrow markedly increased within 10 days, less than
one week after formation of palpable tumors at the injection site in
muscle (BM: 2.1061.75% DsRed
+ cells increased to
48.3863.28%; spleen: 2.8960.35% DsRed+ cells increased to
46.8565.18%, Fig. S3C and data not shown, 10 out of 15 animals
examined). Thus, as in the p16p19
2/2; Kras(G12V) model, in the
Figure 4. Phenotypic profiling of bone marrow and spleen cells indicates dissemination of tumor cells from hindlimb muscle into
hematopoietic organs. (A) H & E staining of bone, spleen and liver from recipients bearing primary myeloid tumor in the muscle, indicating
aggressive infiltration of myeloid leukemia cells (60x) to distant anatomical locations. (B, C) Representative flow cytometry data demonstrating a
similar immunophenotype of tumor cells in BM (B) and spleen (C) as that seen in the primary histiocytic sarcoma initiated in muscle (see Fig. 2D).
doi:10.1371/journal.pone.0044044.g004
Histiocytic Sarcoma in Mouse Muscle
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recipient mice occurs following extramedullary tumor formation,
with fluorescently marked tumor cells migrating from the injection
site in the hindlimb muscle to the BM and spleen.
Discussion
The work described here establishes a novel in vivo lentivirus-
induced histiocytic/myeloid sarcoma model in immuno-compro-
mised mice, combining ablation of the tumor suppressor gene
locus p16p19 and ectopic expression of constitutively active
oncogenic Kras(G12V). P16p19
2/2; Kras(G12V) tumor cells exhibit
typical features of histiocytic sarcoma, including a predominant
lack of expression of lymphocyte markers, positive expression of
histiocyte/macrophage markers, and round to oval shaped cells
with abundant, eosinophilic cytoplasm and nuclear atypia.
P16p19
2/2; Kras(G12V) induced murine histiocytic sarcomas are
aggressive neoplasms, and all tumor-bearing mice ultimately
succumb to progressive leukemic symptoms [36].
The events that drive the formation of murine histiocytic
sarcomas versus murine histiocytic leukemias as the first manifes-
tation of a histiocytic neoplasm remain unclear. Murine histiocytic
tumors induced by P16p19
2/2; Kras(G12V) tumor cells show
evidence of a monocytic origin. A recent report showed that mice
with coincident loss of Dok-1, Dok-2 and Dok-3 genes develop
highly invasive and transplantable histiocytic sarcoma endoge-
nously, and Dok-1/2/3
2/2 macrophages demonstrate enhanced
proliferation ability [37], suggesting origination of the disease in
monocytic cells. Histiocytic sarcoma also has been observed
sporadically in pEm-Ras transgenic mice [38], and p16p19
2/2 mice
develop histiocytic sarcoma with homozygous loss of Pten [39].
Deficiency of Pten leads to activation of Akt, as well as ERK1 and
ERK2 in the histiocytic sarcoma cells, indicating hyperactivation
of the Kras-MAPK pathway [39]. The majority (75%) of Pten
2/
Figure 5. Primary histiocytic sarcomas are serially transplantable in NOD.SCID mice. (A) Schematic diagram showing experimental design
for secondary transplantation. GFP
+ cells were sorted from freshly isolated primary tumor, induced initially by transplantation of gene-modified bone
marrow cells into the cardiotoxin pre-injured muscle of NOD.SCID recipients, and injected into gastrocnemius muscle of secondary NOD.SCID
recipients at different cell dosages (100 000, 10 000, 2 000, or 200 cells) following cardiotoxin pre-injury. (B) H & E staining of tumor cells (60x) in
skeletal muscle of a secondary recipient. Immunohistochemical staining of secondary tumors shows positive staining for the myeloid marker Mac2,
and negative staining of B220 and Ter119 (40x). (C) H & E staining of liver and spleen from secondary recipient mouse, showing aggressive infiltration
of myeloid leukemia cells (60x).
doi:10.1371/journal.pone.0044044.g005
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2/2 mice show a biphasic pattern of both lymphoblastic
lymphoma (with a predominance of B- over T-cell lymphoma) and
histiocytic sarcoma [39]. In this regard, it is intriguing that in our
study, we observed variable expression of the lymphoid marker
CD8 in a subset of leukemic mice transplanted intravenously with
p16p19
2/2; Kras(G12V) cells, whereas CD8 was less frequently
expressed in histiocytic sarcomas generated by intramuscular
transplantation of the same donor cell population. These data
reinforce the previously suggested association of lymphomatous
disease with histiocytic sarcoma [39], and suggest that the
anatomical location of tumor origination may influence the
manifestation of this biphenotypic pattern.
P16P19 proteins typically act as tumor suppressors for T cell
and B cell malignancies [28], while Kras mutation induces myeloid
leukemias [13]. Of note, in both the p16p19
2/2; Kras(G12V) and
MLL-AF9 sarcoma models studied here, BM cells were cultured
with a cytokine cocktail briefly (3 hr) after isolation and prior to
intramuscular injection (see Materials and Methods). We cannot rule
out the possibility that selective pressure from the cytokines
possibly confers a myeloid bias on the engrafting cells [40].
Nonetheless, given prevalent in vivo data from murine leukemia
models endogenously expressing either of the oncogenic combi-
nations employed here [25,41–43], it is reasonable to expect that
culture conditions had only a minor impact on the lineage decision
of the histiocytic tumor-initiating cells.
These studies demonstrate clear similarities between murine
histiocytic sarcoma and murine histiocytic leukemia cells estab-
lished by injection of the same oncogenetically modified BM cells
in distinct anatomical locations (muscle vs. blood). A growing
number of studies indicate that hematopoietic and leukemic cells
functionally interact with a number of different ‘‘niche’’ cells in the
BM, e.g., osteolineage cells, mesenchymal cells, reticular cells,
endothelial cells, and adipocytes, as reviewed in [44]. These bi-
directional interactions are mediated by an array of molecular and
cellular signaling pathways, such that perturbations in microen-
vironmental regulators can influence both normal hematopoiesis
and leukemic progression [45]. In particular, Wei et al reported
that the lineage fate of the human Mll-AF9 leukemia cells in mice
could be altered by manipulating growth signals or recipient strain
[46]. Furthermore, mice with AML induced by co-expression of
BCR/ABL and the Nup98/HoxA9 fusion protein showed a loss of
osteolineage cells in the marrow, which may have contributed to
the underlying pancytopenia [47]. Finally, ‘‘niche’’-specific dele-
tion of the microRNA processing enzyme Dicer (using conditional
ablation in mouse osteolineage cells) was shown to be sufficient to
drive the development of a hematopoietic malignancy that
requires this altered microenvironment for its continued propaga-
tion [48]. Yet, despite clear evidence of functional cross-talk
between leukemic and niche cells in the marrow, much remains to
be discovered about the role of the ‘‘niche’’ in the initiation and
progression of extramedullary hematopoietic malignancy in vivo.
Interestingly, the murine histiocytic sarcoma/leukemia models
described here indicate a dominant influence of cell-autonomous,
as opposed to microenvironmental, signals in the development of
Figure 6. Clonality analysis for genomic DNA samples extracted from primary and secondary histiocytic sarcomas and BM samples.
(A) Genomic DNA was extracted from primary and secondary tumors, and subjected to LM-PCR assay. Electrophoretic results of the final products are
shown. Numbers at top of gel refer to sample numbers: No. 1 to 6 are primary tumors, No. 7 is a secondary tumor transplanted using GFP
+ tumor
cells from sample No. 4. All tumors possess an average of three integration sites, demonstrated by distinct numbers and sizes of bands (yellow
numbers on the gel). HEK293T cells were transduced with the same virus and subject to LM-PCR as control. Size markers (100 bp ladder, size of
individual bands indicated in red text) shown at left. (B) Genomic DNA was extracted from BM samples of the same set of NOD.SCID mice bearing
primary and secondary tumors as analyzed in (A). DNA was subjected to LM-PCR assay. Electrophoretic results of the final products are shown. All BM
samples possess an average of three to four integration sites. Bands unique of bone marrow samples are indicated by white arrowheads. Size markers
(100 bp ladder) shown at left.
doi:10.1371/journal.pone.0044044.g006
Histiocytic Sarcoma in Mouse Muscle
PLOS ONE | www.plosone.org 8 August 2012 | Volume 7 | Issue 8 | e44044these malignancies. Whether arising initially in the skeletal muscle
or hematopoietic tissue, the histiocytic sarcoma and leukemia cells
induced by p16p19 deletion and Kras activation share nearly
identical morphological, phenotypic, and histopathological fea-
tures. Moreover, both neoplasms progress to systemic disease with
similar kinetics and dissemination patterns. These findings de-
emphasize possible cell-non-autonomous effects of the microenvi-
ronment in which tumors are initiated as critical determinants of
disease phenotype or progression, and highlight instead the strong
influence of a cell-autonomous oncogenic program in specifying
the emergence of these hematopoietic tumors.
The histiocytic sarcomas and leukemias reported here uniformly
express high levels of CD47. Also known as Integrin Associated
Protein (IAP), CD47 acts as a ‘‘don’t eat me’’ signal, such that cells
with high surface expression of CD47 escape integrin-mediated
phagocytosis and death [49]. As previously reported, circulating
hematopoietic stem cells, human and mouse myeloid leukemia
cells, human bladder tumor-initiating cells, and multiple myeloma
cells all express CD47 at an elevated level, and antagonistic
treatment with anti-CD47 antibody both in vivo and ex vivo can
induce remission of these cancers in mouse and xenograft models
[50–53], suggesting that strategies targeting CD47 may provide
promising therapeutic avenues in a variety of malignancies,
regardless of the underlying oncogenetic lesions. As the histiocytic
(myeloid) sarcomas studied here included a majority population of
CD47
+ tumor cells, the detection and targeting of CD47 in these
tumors may present a useful therapeutic target. Related to this,
recent studies have identified .20 distinct amino acid and
glycosylation differences in the CD47 ligand SIRP-a (signal
regulatory protein-a) in NOD.SCID mice (as compared to other
mouse strains, including C57BL/6) [54]. SIRP-a is expressed by
macrophages and inhibits their phagocytic function when bound
by CD47 [55]. Protein coding as well as post-translational
polymorphisms in SIRP-a correlate directly with the higher
engraftment capacity in NOD.SCID mice of transplanted human
hematopoietic stem cells [54]. Based on these findings, it is
tempting to speculate that differences in the capacity for or
consequences of recognition of tumor cell-expressed CD47 by
SIRP-a-expressing macrophages in NOD.SCID versus C57BL/6
mice may contribute to the ability of intra-muscularly injected
p16p19
2/2; Kras(G12V) tumor cells to generate histiocytic
sarcomas in NOD.SCID but not C57BL/6 recipients, as reported
here.
In summary, this work indicates that study of histiocytic
(myeloid) sarcoma need not be limited to the few spontaneously
emergent models currently available [37–39]. Through direct ex
vivo modification and transplantation of oncogene-modified
hematopoietic lineage cells, we established a rapid and reproduc-
ible system for the generation of this extramedullary tumor, and
showed that this model recapitulates the natural progression of the
disease in leukemia patients. Moreover, the tumor cells share
highly similar features irrespective of the microenvironment at the
site of initiation. Future studies using this model to uncover the
molecular mechanisms that drive the establishment and dissem-
ination of these malignancies will aid in the rapid diagnosis and
effective treatment of these high risk hematopoietic tumors.
Materials and Methods
Mouse husbandry and breeding
6–10 week old NOD.CB17-Prkdcscid/J (NOD.SCID) mice
(JAX, Bar Harbor, Maine) and p16p19
2/2 mice (B6.129
background, NIH/Mouse Models of Human Cancer Consortium)
were bred and maintained at the Joslin Diabetes Center Animal
Facility.
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal experiments were approved by the Joslin Diabetes Center
Institutional Animal Care and Use Committee (Protocol 04-01 to
Amy Wagers). All surgeries were performed under anesthesia, and
all efforts are made to minimize suffering. Animals were humanely
sacrificed prior to tissue collection.
Preparation of lentivirus
The Kras(G12V)-IRES-GFP pGIPZ plasmid was a gift from Dr.
Junhao Mao (University of Massachusetts, Worcester, MA). The
Kras(G12V)-IRES-GFP pGIPZ plasmid (10 mg) or pGIPZ vector
plasmid (10 mg, Open Biosystems, Rockford, IL), the HIV gag-pol-
REV expression plasmid pCMV-dR8.91 (6.5 mg) and the envelope
expression plasmid pMD2.VSV.G (3.5 mg) were co-transfected
into 293 T cells with Fugene 6 (Roche Indianapolis, IN) on Day 1.
HEK 293T cell line was a gift from former Gary D. Gilliland’s lab
[56]. Medium was changed every day for the next 3 days, and
supernatant collected on Days 3 and 4. Supernatant was
concentrated by ultracentrifugation at 20,000 rpm for 3 hours at
4uC (Beckman L7 ultracentrifuge). Lentivirus was titrated and
then stored at 280uC for #3 weeks prior to use. Titration of
lentivirus was performed using 293 T cells. The percentage of
GFP+ cells at 72 hrs post infection was determined using flow
cytometry.
Lentiviral transduction of bone marrow cells
Freshly isolated bone marrow (BM) cells were plated in Iscove’s
Modified Dulbecco’s Medium (IMDM) (31980, Gibco, Grand
Island, NY) containing 5% fetal bovine serum (FBS), 1%
penicillin/streptomycin, 200 mM glutamine, 1% non-essential
amino acids, 1% sodium pyruvate, 50 mM 2-mercaptoethanol,
stem cell factor (SCF, 10 ng/ml, Peprotech, Rocky Hill, NJ), Flt3-
L (10 ng/ml, Peprotech), IL-11 (10 ng/ml, Peprotech), thrombo-
poietin (TPO, 10 ng/ml, Peprotech), IL-6 (10 ng/ml, Peprotech),
and IL-3 (10 ng/ml, Peprotech). Bone marrow cells were spin-
infected with 8 mg/ml polyprene and lentivirus (MOI of 0.1–0.5),
at 2,500 rpm for 90 min. BM cells were then incubated for
3 hours at 37uC, counted and injected into NOD.SCID mice.
Tumor induction
Lentivirally transduced cells were washed and resuspended in
Hank’s balanced salt solution (HBSS) containing 2% FBS. Cells
were injected retro-orbitally using a 28G 1/2 insulin syringe, or
into the gastrocnemius muscles of isofluorane anesthetized
NOD.SCID mice using a transdermally inserted dental needle
attached to a Hamilton syringe via polyethylene tubing. Recipient
muscles were pre-injured 24 hours before cell implantation by
injection of 25 ml of a 0.03 mg/ml solution of cardiotoxin (from
Naja mossambica, Sigma, St. Louis, MO). Muscle pre-injury has
been shown in previous studies [57] to enhance the engraftment of
transplanted muscle precursor cells, although pre-injury was not
required for induction of murine histiocytic sarcoma (see Table 1).
For secondary transplantation, tumor tissue was harvested from
tumor-bearing mice, dissociated to generate single cell suspen-
sions, and then GFP
+ sarcoma cells were isolated by Fluorescence
Activated Cell Sorting (FACS) (see Cell Isolation Procedures for
additional information). Recovered cells were suspended in HBSS
with 2% FBS and injected into the cardiotoxin injured gastroc-
nemius muscles of secondary recipient mice, as described above.
Histiocytic Sarcoma in Mouse Muscle
PLOS ONE | www.plosone.org 9 August 2012 | Volume 7 | Issue 8 | e44044Histology/Immunohistochemistry
Tissues were fixed in 4% paraformaldehyde for 3–5 hours and
embedded in paraffin. Sections (4 micron) were stained with
Hematoxylin & Eosin (H&E) or subjected to immunohistochem-
istry staining at the Specialized Histopathology Core Facility of the
Dana-Farber/Harvard Cancer Center using the following anti-
bodies: GFP (1:1500 in EDTA, ab6556, Abcam, Cambridge, MA),
Ki67 (1:250 in EDTA, VP-RM04, Vector Labs, Burlingame, CA),
CD34 (1:100 in citrate, ab8158, Abcam), MPO (1:2000 in EDTA,
A0398, Dako, Carpinteria, CA), B220 (1:200 in citrate, 550286,
BD Pharmingen, Franklin Lakes, NJ), Ter119 (1:2000 in citrate,
550565, BD Pharmingen).
Cell isolation procedures
Bone marrow cells were flushed from femurs and tibias with
HBSS containing 2% FBS. Spleen cells were isolated by
mechanical dissociation in HBSS supplemented with 2% FBS.
Muscle tumors were digested in DMEM +0.2% collagenase type II
(Invitrogen) for 90 minutes at 37uC in a shaking water bath,
triturated to disrupt the remaining tumor pieces and filtered
through a 70 mm cell strainer. Red blood cells were lysed from all
cell preparations using ACK lysing buffer (Lonza, Hopkinton,
MA). Cells were resuspended in HBSS with 2% FBS for
subsequent procedure and analyses.
Flow cytometry analysis
Flow cytometry was performed as described [58]. Non-specific
antibody binding was blocked with rat IgG (Sigma) for 15 minutes
on ice. Antibody staining was performed for 20 minutes on ice.
The following antibodies were used: PE-CD4 (100408, BioLegend,
San Diego, CA), PECy7-CD8 (100722, BioLegend), APC-Mac1
(17-0112-82, eBioscience, San Diego, CA), APCCy7-Gr1 (108424,
BioLegend), APC-Ter119 (116212, BioLegend), PE-CD71
(113808, BioLegend), PE-CD48 (103405, BioLegend), APC-
CD47 (17-0471, eBioscience). Prior to FACS, cells were suspended
in HBSS containing 2% FBS and 1 mg/ml propidium iodide to
mark non-viable cells (which were excluded from analysis).
Limiting Dilution Analyses
Limiting dilution analyses were performed based on Bonnefoix
et al. [59] using the limdil function of the ‘StatMod’ package
(author G.K. Smyth, http://bioinf.wehi.edu.au/software/limdil/),
part of the R statistical software project (http://www.r-project.
org).
Analysis of Proviral integration sites
Proviral integration sites were isolated using ligation-mediated
(LM)-PCR as described [60]. Briefly, 200 ng of genomic DNA was
digested with Tsp509I (New England Biolabs, Ipswich, MA) and
then subjected to linear amplification using the biotinylated primer
Lenti LTRI (59-GAGCTCTCTGGCTAACTAGG-39). The la-
beled amplification product was then purified using streptavidin
coated paramagnetic Dynabeads (Invitrogen, Carlsbad, CA) and
was subsequently subjected to ligation with a blunt-ended linker
cassette that had been synthesized by hybridization of the
oligonucleotides OC1 (59-GACCCGGGAGATCTGAATT-
CAGTGGCACAGCAGTTAGG-39) and OC2 (59-
CCTAACTGCTGTGCCACTGAATTCAGATC-39). The liga-
tion product was amplified via two rounds of nested PCR, using
the primers Lenti LTRII (59-AGCTTGCCTTGAGTGCTTCA-
39) and OCI (59-GACCCGGGAGATCTGAATTC-39) in the first
round of amplification; and Lenti LTRIII (59-AG-
TAGTGTGTGCCCGTCTGT-39) and OCII (59-AGTGGCA-
CAGCAGTTAGG-39) in the second round of amplification.
Reaction conditions were as described [60]. Amplification
products were analyzed by agarose gel electrophoresis. Selected
amplification products were isolated using Gel Extraction Kit
(Qiagen), and cloned into the pCR2.1- TOPO vector (TOPO TA
cloning kit, Invitrogen). Proviral integration sites were subsequent-
ly sequenced using M13 forward and reverse primers and the
results were aligned against the mouse genome using Basic Local
Alignment Search Tool (BLAST) program (http://blast.ncbi.nlm.
nih.gov/Blast.cgi).
Generation and isolation of MLL-AF9 leukemia cells
MLL-AF9 mouse leukemias were generated in Dr. David
Scadden’s laboratory as described below. Actin-DsRED mice
(JAX) were backcrossed for 10 generations onto C57BL/6J mice
(JAX). These mice were sacrificed four days after injection with
150 mg/kg 5FU. BM cells were isolated from femurs and tibias,
and red blood cells were lysed using ACK lysing buffer (Lonza).
Cells were incubated in RPMI supplemented with 20% FBS, 1%
Pen-Strep, 6 ng/ml of IL-3 (Peprotech), 10 ng/ml of TPO
(Peprotech), 10 ng/ml of IL-6 (Peprotech), at 37uC 5% CO2
overnight. MLL-AF9 was introduced by spin-infection (1 000 g for
90 minutes) using a retroviral vector (MSCV-MLL-AF9-neo) [35]
in the presence of 8 mg/ml polybrene (Millipore, Billerica, MA).
Virus-containing media was removed 4 hours after spin-infection,
and 4610
6 live cells per mouse were injected into lethally
irradiated (9Gy) C57BL/6 recipient mice 12 hours after viral
infection. The mice were sacrificed once they became moribund.
BM cells were isolated as described above, and subjected to ACK
lysis. 200 000 cells were injected into sublethally irradiated (4.5
Gy) C57BL/6 recipients. Once these mice were moribund, ACK-
lysed live BM cells were isolated as described above and 1610
6
cells/mouse were used for intramuscular injections.
Supporting Information
Figure S1 Tumorigenesis in NOD.SCID recipients of p16p19
2/
2; Kras(G12V) BM cells. (A) Gross anatomy of primary histiocytic
sarcoma in the hind-limb of a recipient NOD.SCID mouse. (B)
Enlarged spleen from a NOD.SCID mouse bearing primary
histiocytic sarcoma. (C) Representative image of spleen and tumor
of a NOD.SCID mouse bearing secondary histiocytic sarcoma. (D)
Representative picture of NOD.SCID mice bearing MLL-AF9
leukemic BM cell- induced histiocytic sarcoma.
(TIF)
Figure S2 List of viral integration sites detected by LM-PCR of
the histiocytic sarcoma samples from NOD.SCID mice in Fig. 6. A
common integration site near the RPS29 locus is highlighted in
red. Interestingly, a recent genetic screen revealed that mutation of
RPS29 abolishes definitive hematopoiesis in zebrafish embryos
(Burns CE et al, 2009), and loss of RPS29 affects the expression of
hemoglobin suggesting a defect in red blood cells differentiation or
hemoglobinization (Taylor AM et al, 2012).
(TIF)
Figure S3 Ds-Red/MLL-AF9 leukemia cells induce histiocytic
sarcoma in intramuscularly-transplanted NOD.SCID recipients.
(A) Transplantation schematics for Ds-Red/MLL-AF9 transplanta-
tion. (B) Representative immunophenotypic profiling of MLL-AD9
induced histiocytic sarcomas. Plots at right are gated for live (PI-)
DsRed
+ cells. (C) Representative frequency of DsRed
+ cells in
bone marrow and spleen of mice in which histiocytic sarcomas
were induced by transplantation of Ds-Red/MLL-AF9-expressing
BM cells. Data collected by flow cytometry at 30 days post
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histiocytic sarcoma, bone marrow, spleen and liver (60x).
(TIF)
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